 Cindy O'Bryant
Concepts (316)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 22 | 2025 | 2202 | 1.810 |
Why?
| | Neoplasms | 32 | 2025 | 2887 | 1.570 |
Why?
| | Antiemetics | 2 | 2024 | 49 | 0.810 |
Why?
| | Piperidines | 3 | 2021 | 218 | 0.760 |
Why?
| | Pyridines | 5 | 2015 | 605 | 0.750 |
Why?
| | Pharmacists | 5 | 2025 | 240 | 0.710 |
Why?
| | Indazoles | 1 | 2021 | 83 | 0.660 |
Why?
| | Anilides | 2 | 2013 | 84 | 0.660 |
Why?
| | Liver | 3 | 2021 | 1893 | 0.640 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 48 | 0.600 |
Why?
| | Immunoconjugates | 2 | 2023 | 138 | 0.590 |
Why?
| | Cisplatin | 5 | 2024 | 336 | 0.590 |
Why?
| | Morpholines | 1 | 2020 | 129 | 0.590 |
Why?
| | Drug Hypersensitivity | 1 | 2020 | 90 | 0.560 |
Why?
| | Drug Interactions | 6 | 2024 | 401 | 0.520 |
Why?
| | Protein Kinase Inhibitors | 5 | 2024 | 974 | 0.490 |
Why?
| | Histone Deacetylase Inhibitors | 3 | 2019 | 220 | 0.480 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2015 | 230 | 0.430 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2020 | 1962 | 0.390 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2026 | 1183 | 0.390 |
Why?
| | Dose-Response Relationship, Drug | 13 | 2021 | 2032 | 0.380 |
Why?
| | Medical Oncology | 3 | 2025 | 332 | 0.380 |
Why?
| | Depsipeptides | 1 | 2012 | 15 | 0.370 |
Why?
| | Quinazolines | 2 | 2011 | 266 | 0.370 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2012 | 45 | 0.360 |
Why?
| | Area Under Curve | 8 | 2021 | 332 | 0.340 |
Why?
| | Pyrazoles | 2 | 2013 | 510 | 0.340 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2026 | 991 | 0.340 |
Why?
| | Sulindac | 2 | 2008 | 16 | 0.330 |
Why?
| | Neuroendocrine Tumors | 1 | 2012 | 114 | 0.330 |
Why?
| | Sirolimus | 1 | 2012 | 281 | 0.330 |
Why?
| | Nitriles | 2 | 2008 | 205 | 0.320 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 444 | 0.320 |
Why?
| | Skin Neoplasms | 2 | 2017 | 847 | 0.310 |
Why?
| | Aged | 31 | 2026 | 26001 | 0.300 |
Why?
| | Middle Aged | 34 | 2026 | 36021 | 0.300 |
Why?
| | Lung Neoplasms | 3 | 2026 | 2652 | 0.280 |
Why?
| | Tosyl Compounds | 1 | 2008 | 16 | 0.280 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 75 | 0.270 |
Why?
| | Drug Dosage Calculations | 1 | 2008 | 27 | 0.270 |
Why?
| | Bone Density Conservation Agents | 1 | 2008 | 81 | 0.270 |
Why?
| | Liver Failure, Acute | 1 | 2008 | 67 | 0.270 |
Why?
| | Androgen Antagonists | 1 | 2008 | 92 | 0.260 |
Why?
| | Food | 1 | 2008 | 150 | 0.250 |
Why?
| | Pain | 3 | 2011 | 784 | 0.250 |
Why?
| | Fasting | 1 | 2008 | 277 | 0.240 |
Why?
| | Breast Neoplasms | 3 | 2023 | 2464 | 0.240 |
Why?
| | Humans | 52 | 2026 | 145305 | 0.230 |
Why?
| | Aged, 80 and over | 10 | 2024 | 8295 | 0.230 |
Why?
| | Osteoporosis | 1 | 2008 | 236 | 0.230 |
Why?
| | Liver Diseases | 2 | 2019 | 305 | 0.230 |
Why?
| | Professional Role | 2 | 2017 | 158 | 0.230 |
Why?
| | Acute Kidney Injury | 3 | 2018 | 870 | 0.220 |
Why?
| | Serotonin 5-HT3 Receptor Antagonists | 1 | 2024 | 5 | 0.220 |
Why?
| | Administration, Oral | 5 | 2012 | 848 | 0.220 |
Why?
| | Female | 36 | 2026 | 78605 | 0.220 |
Why?
| | Deoxycytidine | 5 | 2011 | 221 | 0.220 |
Why?
| | Platinum | 1 | 2024 | 52 | 0.210 |
Why?
| | Maximum Tolerated Dose | 10 | 2020 | 212 | 0.210 |
Why?
| | Male | 35 | 2026 | 72628 | 0.210 |
Why?
| | Hedgehog Proteins | 2 | 2017 | 197 | 0.210 |
Why?
| | Pancreatic Neoplasms | 1 | 2012 | 928 | 0.200 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1525 | 0.200 |
Why?
| | Nausea | 4 | 2020 | 111 | 0.200 |
Why?
| | Adult | 28 | 2025 | 40627 | 0.200 |
Why?
| | Midazolam | 1 | 2024 | 72 | 0.200 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2024 | 93 | 0.200 |
Why?
| | Angiogenesis Inhibitors | 4 | 2010 | 237 | 0.200 |
Why?
| | Vomiting | 3 | 2020 | 131 | 0.180 |
Why?
| | ErbB Receptors | 2 | 2017 | 630 | 0.170 |
Why?
| | Apoptosis | 3 | 2008 | 2430 | 0.170 |
Why?
| | Sulfonamides | 2 | 2019 | 581 | 0.170 |
Why?
| | Cohort Studies | 5 | 2020 | 5982 | 0.170 |
Why?
| | Prostatic Neoplasms | 1 | 2008 | 979 | 0.170 |
Why?
| | Lymphoma | 2 | 2016 | 233 | 0.160 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2023 | 216 | 0.160 |
Why?
| | Pyrimidines | 2 | 2024 | 533 | 0.160 |
Why?
| | Trastuzumab | 2 | 2023 | 118 | 0.160 |
Why?
| | Benzoxazoles | 1 | 2020 | 20 | 0.160 |
Why?
| | Fluorouracil | 4 | 2011 | 235 | 0.160 |
Why?
| | Drug Evaluation | 1 | 2020 | 79 | 0.160 |
Why?
| | Azepines | 1 | 2020 | 107 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1420 | 0.150 |
Why?
| | Patient Care Team | 1 | 2025 | 692 | 0.150 |
Why?
| | Hydroxamic Acids | 1 | 2019 | 94 | 0.150 |
Why?
| | Analgesics, Opioid | 1 | 2008 | 1145 | 0.140 |
Why?
| | TWEAK Receptor | 1 | 2017 | 6 | 0.130 |
Why?
| | Pharmacogenomic Variants | 1 | 2017 | 33 | 0.130 |
Why?
| | Hematology | 1 | 2017 | 21 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2014 | 557 | 0.130 |
Why?
| | Models, Biological | 1 | 2024 | 1823 | 0.130 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 48 | 0.130 |
Why?
| | Pharmaceutical Services | 1 | 2017 | 78 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2020 | 548 | 0.120 |
Why?
| | Maytansine | 1 | 2016 | 18 | 0.120 |
Why?
| | Aminoglycosides | 1 | 2016 | 29 | 0.120 |
Why?
| | Specialty Boards | 1 | 2016 | 43 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2017 | 292 | 0.110 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2926 | 0.110 |
Why?
| | Pain Management | 2 | 2017 | 407 | 0.110 |
Why?
| | Drugs, Investigational | 1 | 2015 | 31 | 0.110 |
Why?
| | Carbazoles | 1 | 2015 | 56 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2016 | 111 | 0.110 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 112 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 437 | 0.110 |
Why?
| | Biomarkers, Tumor | 4 | 2010 | 1325 | 0.110 |
Why?
| | American Heart Association | 1 | 2016 | 356 | 0.110 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2014 | 12 | 0.100 |
Why?
| | Insurance Claim Review | 1 | 2014 | 83 | 0.100 |
Why?
| | Drug Administration Schedule | 5 | 2019 | 783 | 0.100 |
Why?
| | Carboplatin | 3 | 2009 | 161 | 0.100 |
Why?
| | Specialization | 1 | 2014 | 136 | 0.100 |
Why?
| | Retrospective Studies | 5 | 2026 | 17149 | 0.090 |
Why?
| | Chronic Pain | 1 | 2017 | 292 | 0.090 |
Why?
| | Gonanes | 1 | 2012 | 28 | 0.090 |
Why?
| | Everolimus | 1 | 2012 | 111 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2010 | 338 | 0.090 |
Why?
| | Signal Transduction | 2 | 2017 | 5239 | 0.090 |
Why?
| | Biomarkers | 3 | 2018 | 4284 | 0.090 |
Why?
| | Erlotinib Hydrochloride | 1 | 2011 | 72 | 0.090 |
Why?
| | Liver Function Tests | 1 | 2011 | 106 | 0.090 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1063 | 0.080 |
Why?
| | Phytotherapy | 1 | 2011 | 74 | 0.080 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 826 | 0.080 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 299 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 762 | 0.080 |
Why?
| | Glucuronidase | 2 | 2008 | 25 | 0.080 |
Why?
| | Antihypertensive Agents | 1 | 2014 | 513 | 0.080 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 47 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2011 | 510 | 0.080 |
Why?
| | Curriculum | 1 | 2017 | 1072 | 0.080 |
Why?
| | Oligosaccharides | 2 | 2008 | 60 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 86 | 0.080 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 31 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2506 | 0.070 |
Why?
| | Drug Monitoring | 1 | 2013 | 396 | 0.070 |
Why?
| | Primary Health Care | 2 | 2017 | 1737 | 0.070 |
Why?
| | Kidney | 1 | 2017 | 1499 | 0.070 |
Why?
| | Cannabinoids | 1 | 2011 | 182 | 0.070 |
Why?
| | Treatment Outcome | 7 | 2015 | 11731 | 0.070 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 451 | 0.070 |
Why?
| | Education, Pharmacy, Continuing | 1 | 2008 | 2 | 0.070 |
Why?
| | Capecitabine | 4 | 2011 | 57 | 0.070 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 684 | 0.070 |
Why?
| | Clinical Competence | 1 | 2017 | 1247 | 0.070 |
Why?
| | Equipment and Supplies | 1 | 2008 | 35 | 0.070 |
Why?
| | Androstadienes | 1 | 2008 | 76 | 0.070 |
Why?
| | Boronic Acids | 1 | 2008 | 37 | 0.070 |
Why?
| | Taxoids | 2 | 2008 | 116 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1568 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2008 | 72 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2008 | 46 | 0.070 |
Why?
| | Marijuana Smoking | 1 | 2011 | 250 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 286 | 0.070 |
Why?
| | Farnesyltranstransferase | 1 | 2007 | 21 | 0.070 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 56 | 0.070 |
Why?
| | Etoposide | 1 | 2008 | 167 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2008 | 81 | 0.070 |
Why?
| | Reference Standards | 1 | 2008 | 178 | 0.070 |
Why?
| | Receptors, Vitronectin | 1 | 2007 | 5 | 0.070 |
Why?
| | Drug Prescriptions | 1 | 2010 | 286 | 0.070 |
Why?
| | Administration, Cutaneous | 1 | 2008 | 125 | 0.070 |
Why?
| | Integrin alphaVbeta3 | 1 | 2007 | 20 | 0.070 |
Why?
| | Pyrazines | 1 | 2008 | 93 | 0.070 |
Why?
| | Snake Venoms | 1 | 2007 | 20 | 0.070 |
Why?
| | Oxycodone | 1 | 2008 | 53 | 0.060 |
Why?
| | Absorptiometry, Photon | 1 | 2008 | 276 | 0.060 |
Why?
| | Benzamides | 1 | 2008 | 227 | 0.060 |
Why?
| | Fatigue | 4 | 2012 | 366 | 0.060 |
Why?
| | Triazoles | 1 | 2008 | 184 | 0.060 |
Why?
| | Delayed-Action Preparations | 1 | 2008 | 184 | 0.060 |
Why?
| | Integrins | 1 | 2007 | 90 | 0.060 |
Why?
| | Pharmacogenetics | 1 | 2008 | 173 | 0.060 |
Why?
| | Anxiety Disorders | 1 | 2010 | 373 | 0.060 |
Why?
| | Alkyl and Aryl Transferases | 1 | 2006 | 31 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2007 | 132 | 0.060 |
Why?
| | Morphine | 1 | 2008 | 171 | 0.060 |
Why?
| | Fentanyl | 1 | 2008 | 127 | 0.060 |
Why?
| | Animals | 6 | 2020 | 38177 | 0.060 |
Why?
| | Indoles | 2 | 2008 | 501 | 0.060 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 115 | 0.060 |
Why?
| | Thiophenes | 1 | 2007 | 128 | 0.060 |
Why?
| | Young Adult | 3 | 2020 | 14163 | 0.060 |
Why?
| | Cell Line, Tumor | 3 | 2020 | 3560 | 0.060 |
Why?
| | Methadone | 1 | 2008 | 122 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 598 | 0.060 |
Why?
| | Societies, Pharmaceutical | 2 | 2017 | 14 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 510 | 0.060 |
Why?
| | Nigeria | 1 | 2025 | 24 | 0.060 |
Why?
| | Risk Factors | 1 | 2020 | 10816 | 0.060 |
Why?
| | Hypertension | 1 | 2014 | 1266 | 0.060 |
Why?
| | Granisetron | 1 | 2024 | 6 | 0.060 |
Why?
| | Protein Binding | 1 | 2011 | 2283 | 0.060 |
Why?
| | Quinuclidines | 1 | 2024 | 11 | 0.060 |
Why?
| | Palliative Care | 2 | 2011 | 1012 | 0.060 |
Why?
| | Ondansetron | 1 | 2024 | 19 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 577 | 0.050 |
Why?
| | Isoquinolines | 1 | 2024 | 44 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 931 | 0.050 |
Why?
| | Occupational Exposure | 1 | 2008 | 354 | 0.050 |
Why?
| | Cannabis | 1 | 2011 | 509 | 0.050 |
Why?
| | Infusions, Intravenous | 2 | 2019 | 423 | 0.050 |
Why?
| | RNA, Catalytic | 1 | 2005 | 189 | 0.050 |
Why?
| | United States | 5 | 2017 | 16051 | 0.050 |
Why?
| | Quinolones | 1 | 2006 | 201 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 764 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6079 | 0.050 |
Why?
| | Prospective Studies | 3 | 2024 | 8011 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2015 | 2182 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2020 | 886 | 0.050 |
Why?
| | Camptothecin | 1 | 2023 | 140 | 0.050 |
Why?
| | Pyrroles | 1 | 2024 | 218 | 0.050 |
Why?
| | Diarrhea | 2 | 2015 | 194 | 0.050 |
Why?
| | Heart Failure | 1 | 2016 | 2331 | 0.050 |
Why?
| | Adolescent | 2 | 2020 | 22507 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1747 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1470 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2020 | 62 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 63 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 139 | 0.040 |
Why?
| | Neutropenia | 2 | 2009 | 155 | 0.030 |
Why?
| | Organic Cation Transporter 2 | 1 | 2017 | 8 | 0.030 |
Why?
| | Glutathione S-Transferase pi | 1 | 2017 | 10 | 0.030 |
Why?
| | Adenine | 1 | 2020 | 339 | 0.030 |
Why?
| | Partial Thromboplastin Time | 2 | 2008 | 50 | 0.030 |
Why?
| | Organic Cation Transport Proteins | 1 | 2017 | 25 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2018 | 334 | 0.030 |
Why?
| | Amidine-Lyases | 1 | 1997 | 1 | 0.030 |
Why?
| | Anemia | 2 | 2009 | 189 | 0.030 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2007 | 26 | 0.030 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 1997 | 54 | 0.030 |
Why?
| | Mixed Function Oxygenases | 1 | 1997 | 49 | 0.030 |
Why?
| | Multienzyme Complexes | 1 | 1997 | 67 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2008 | 5883 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 157 | 0.030 |
Why?
| | Paclitaxel | 2 | 2009 | 256 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2017 | 118 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 1003 | 0.030 |
Why?
| | Cardiotoxins | 1 | 2015 | 3 | 0.030 |
Why?
| | Drug Eruptions | 1 | 2015 | 28 | 0.030 |
Why?
| | Mucositis | 1 | 2015 | 20 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 383 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2017 | 124 | 0.030 |
Why?
| | Analgesics | 1 | 1997 | 231 | 0.030 |
Why?
| | Pharmacy Residencies | 1 | 2014 | 8 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2009 | 1718 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5431 | 0.030 |
Why?
| | Drug Discovery | 1 | 2015 | 155 | 0.030 |
Why?
| | Students, Pharmacy | 1 | 2014 | 99 | 0.020 |
Why?
| | Stroke Volume | 1 | 2015 | 653 | 0.020 |
Why?
| | Electrocardiography | 1 | 2015 | 663 | 0.020 |
Why?
| | Dioxoles | 1 | 2011 | 9 | 0.020 |
Why?
| | Tetrahydroisoquinolines | 1 | 2011 | 8 | 0.020 |
Why?
| | Biological Availability | 1 | 2011 | 142 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2016 | 603 | 0.020 |
Why?
| | Mice | 3 | 2020 | 18394 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3613 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 381 | 0.020 |
Why?
| | Massage | 1 | 2010 | 42 | 0.020 |
Why?
| | Alopecia | 1 | 2009 | 37 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 74 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4310 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2014 | 696 | 0.020 |
Why?
| | Celecoxib | 1 | 2008 | 41 | 0.020 |
Why?
| | Bortezomib | 1 | 2008 | 55 | 0.020 |
Why?
| | Maximum Allowable Concentration | 1 | 2008 | 16 | 0.020 |
Why?
| | Floxuridine | 1 | 2008 | 5 | 0.020 |
Why?
| | Protein Kinase C beta | 1 | 2008 | 21 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2010 | 268 | 0.020 |
Why?
| | Dibenzocycloheptenes | 1 | 2007 | 5 | 0.020 |
Why?
| | Platelet Factor 4 | 1 | 2008 | 36 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2008 | 93 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2007 | 121 | 0.020 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2007 | 18 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2007 | 56 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2008 | 139 | 0.020 |
Why?
| | Protein Prenylation | 1 | 2006 | 19 | 0.020 |
Why?
| | Carcinoid Tumor | 1 | 2006 | 21 | 0.020 |
Why?
| | Leiomyosarcoma | 1 | 2006 | 28 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2008 | 252 | 0.020 |
Why?
| | Heparin | 1 | 2008 | 244 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2008 | 205 | 0.020 |
Why?
| | Cell Adhesion Molecules | 1 | 2007 | 178 | 0.010 |
Why?
| | Risk | 1 | 2008 | 912 | 0.010 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2006 | 105 | 0.010 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 216 | 0.010 |
Why?
| | Inflammation | 1 | 1997 | 2881 | 0.010 |
Why?
| | Fibroblast Growth Factors | 1 | 2006 | 188 | 0.010 |
Why?
| | Antibody Formation | 1 | 2006 | 294 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 109 | 0.010 |
Why?
| | Monocytes | 1 | 2008 | 538 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1268 | 0.010 |
Why?
| | Disease Progression | 1 | 2012 | 2855 | 0.010 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 257 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2006 | 234 | 0.010 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 177 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1735 | 0.010 |
Why?
| | Gene Expression | 1 | 2007 | 1490 | 0.010 |
Why?
| | Gastrointestinal Tract | 1 | 2004 | 208 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2007 | 872 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 4104 | 0.010 |
Why?
| | Melanoma | 1 | 2006 | 761 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2006 | 849 | 0.010 |
Why?
| | Carrageenan | 1 | 1997 | 8 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3888 | 0.010 |
Why?
| | Bradykinin | 1 | 1997 | 48 | 0.010 |
Why?
| | Substance P | 1 | 1997 | 39 | 0.010 |
Why?
| | Lyases | 1 | 1997 | 16 | 0.010 |
Why?
| | Edema | 1 | 1997 | 124 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1997 | 392 | 0.010 |
Why?
| | Serotonin | 1 | 1997 | 294 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 7186 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1630 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1997 | 2158 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1997 | 2541 | 0.010 |
Why?
| | Rats | 1 | 1997 | 5616 | 0.000 |
Why?
|
|
O'Bryant's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|